Catalog No.
YHF82101
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Met1-Ala326
Predicted molecular weight
39.25 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q00534
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Cell division protein kinase 6, Cyclin-dependent kinase 6, Serine/threonine-protein kinase PLSTIRE, CDKN6, CDK6
The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)., PMID:40511560
Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy., PMID:40504547
Interaction of xanthatin as a bioactive sesquiterpene lactone with cyclin-dependent kinase-6 enzyme to regulate prostate cancer cell proliferation., PMID:40447006
Updated efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in elderly women with HR+/HER-2 metastatic or advanced breast cancer: patient-level network meta-analysis., PMID:40440494
Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China., PMID:40426093
Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans., PMID:40418395
Carboxylesterase 1 regulates peroxisome proliferator-activated receptor gamma to inhibit the growth and metastasis of breast cancer cells., PMID:40418235
Genomics-led approach to drug testing in models of undifferentiated pleomorphic sarcoma., PMID:40415599
A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer., PMID:40409404
Limocitrin induced cellular death through ERK pathways in human oral squamous cell cancer., PMID:40404781
Repurposing HIV protease inhibitors as senotherapeutic agents in cervical cancer: Dual targeting of CDK1/6-cell cycle arrest and p53/p21/p16 signaling axis., PMID:40403681
Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus-Negative, Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm, Phase II Trial., PMID:40403207
miRNA Differential Expression Profile Analysis and Identification of Potential Key Genes in Active Tuberculosis., PMID:40387517
Dynamics insights into CDK4/6-CyclinD1 complex stability modulated by abemaciclib., PMID:40376755
Rationally designed Pyrazolo[1,5-a]pyrimidines as dual inhibitors of CA IX/XII and CDK6: A novel approach for NSCLC treatment., PMID:40373635
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy., PMID:40369610
Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4/6 inhibitors: A comprehensive review., PMID:40367730
Combination of autophagy inhibitors with high-dose CDK4/6 inhibitors offers new hope for advanced HR+/HER2- breast cancer., PMID:40347937
lncRNA AK159072 Promotes Myoblast Proliferation and Muscle Regeneration Through Activation of Akt/Foxo1 Pathway., PMID:40341721
Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis., PMID:40340824
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer., PMID:40327300
Epimedii Folium and Curculiginis Rhizoma ameliorate age-related cognitive decline and neuroinflammation through modulation of the NLRP3 inflammasome., PMID:40319931
Design, synthesis, and biological evaluation of novel CDK4/6 and BRD4 dual inhibitors for treatment of KRAS-mutant NSCLC., PMID:40311163
F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression., PMID:40307251
Genetic alterations of Cyclin D-CDK4/6-INK4-RB pathway in prostate cancer., PMID:40304827
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer., PMID:40285528
Anticancer potential of novel benzothiazolyl piperidine-3-carboxamide derivatives as CDKs and VEGFR2 multi-target kinase inhibitors., PMID:40278942
Effects of Benzo[a]Pyrene Exposure on Lung Cancer: A Mechanistic Study of Epigenetic m6A Levels and YTHDF1., PMID:40278596
Phytochemical analysis and anti-lung cancer effects in vitro and in vivo of Eomecon chionantha root., PMID:40274030
Stabilization of GTSE1 by cyclin D1-CDK4/6-mediated phosphorylation promotes cell proliferation with implications for cancer prognosis., PMID:40272409
27-hydroxycholesterol impairs placental development via p53/p21/Cdk6 pathway: Implications for nutrient transport and cellular senescence., PMID:40268063
Surrogate molecular classification of LAR breast cancer in routine workflow., PMID:40265610
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty., PMID:40262369
CDK4/6 Inhibitor Can Improve Niraparib Sensitivity and Reverse Acquired Drug Resistance Through Endonuclease G Nuclear Translocation in BRCA Wild-Type Ovarian Cancer: A Vitro Study., PMID:40256809
Cardiovascular Adverse Events and Associated Costs of CDK4/6 Inhibitors in Patients With Breast Cancer., PMID:40250478
Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast Cancer., PMID:40244377
Impact of Patient Profile on CDK4/6 Inhibitor Therapy Outcomes: A Real-World Data Analysis., PMID:40244189
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer., PMID:40237878
A drug that induces the microRNA miR-124 enables differentiation of retinoic acid-resistant neuroblastoma cells., PMID:40233178
Molecular docking analysis of pyrrole derivatives with different breast cancer targets., PMID:40230904
CDK4/6 inhibitor-associated vortex keratopathy: a case report., PMID:40229836
Bexarotene Promotes Neuroblastoma SH-SY5Y Cell Differentiation to Mature Neurons with Decreased Proliferation., PMID:40229457
Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2- advanced or metastatic breast cancer in China., PMID:40229346
Potential Value of AURKA and CDK6 Amplification for the Response of Patients With Gastric Cancer to Neoadjuvant Chemotherapy., PMID:40222043
Raddeanin A exerts potent efficacy against non-small cell lung cancer by inhibiting cyclin-dependent kinase 6., PMID:40215679
CDK4 loss-of-function mutations cause microcephaly and short stature., PMID:40210435
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer., PMID:40200428
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment., PMID:40200094
Ginsenoside Rg5 inhibits the proliferation of HeLa cell through cell cycle pathway., PMID:40196332
Prognostic markers and molecular pathways in primary colorectal cancer with a high potential of liver metastases: a systems biology approach., PMID:40190820
For research use only. Not for human or drug use.
